Entegrion Awarded up to $43.7 Million from Department of Defense for a Blood Product Technology

Entegrion announced today it has received a contract valued up to $43.7 million from the Department of Defense. The RTP life sciences development company will apply the funding to the clinical development of Resusix®, its proprietary dehydrated pathogen-inactivated human plasma that holds promise as a substitute for fresh frozen plasma (FFP) in certain applications. [read full article at PRWeb]